Extracting Potential New Targets for Treatment of Adenoid Cystic Carcinoma Using Bioinformatic Methods

Overview

Journal Iran Biomed J

Specialties Biology
General Medicine

Date 2023 Oct 24

PMID 37873683

Authors

Tayebeh Forooghi Pordanjani

Bahareh Dabirmanesh

Peyman Choopanian

Mehdi Mirzaie

Saleh Mohebbi

Khosro Khajeh

Affiliations

Soon will be listed here.

Abstract

Background: Adenoid cystic carcinoma is a slow-growing malignancy that most often occurs in the salivary glands. Currently, no FDA-approved therapeutic target or diagnostic biomarker has been identified for this cancer. The aim of this study was to find new therapeutic and diagnostic targets using bioinformatics methods.

Methods: We extracted the gene expression information from two GEO datasets (including GSE59701 and GSE88804). Different expression genes between adenoid cystic carcinoma (ACC) and normal samples were extracted using R software. The biochemical pathways involved in ACC were obtained by using the Enrichr database. PPI network was drawn by STRING, and important genes were extracted by Cytoscape. Real-time PCR and immunohistochemistry were used for biomarker verification.

Results: After analyzing the PPI network, 20 hub genes were introduced to have potential as diagnostic and therapeutic targets. Among these genes, PLCG1 was presented as new biomarker in ACC. Furthermore, by studying the function of the hub genes in the enriched biochemical pathways, we found that insulin-like growth factor type 1 receptor and PPARG pathways most likely play a critical role in tumorigenesis and drug resistance in ACC and have a high potential for selection as therapeutic targets in future studies.

Conclusion: In this study, we achieved the recognition of the pathways involving in ACC pathogenesis and also found potential targets for treatment and diagnosis of ACC. Further experimental studies are required to confirm the results of this study.

References

Andersson M, Aman P, Stenman G . IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors. Cells. 2019; 8(8). PMC: 6721700. DOI: 10.3390/cells8080913. View

Liu Z, Gao J, Yang Y, Zhao H, Ma C, Yu T . Potential targets identified in adenoid cystic carcinoma point out new directions for further research. Am J Transl Res. 2021; 13(3):1085-1108. PMC: 8014416. View

Mitani Y, Rao P, Futreal P, Roberts D, Stephens P, Zhao Y . Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res. 2011; 17(22):7003-14. PMC: 3225955. DOI: 10.1158/1078-0432.CCR-11-1870. View

Konze K, Ma A, Li F, Barsyte-Lovejoy D, Parton T, MacNevin C . An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013; 8(6):1324-34. PMC: 3773059. DOI: 10.1021/cb400133j. View

Siddle K . Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. 2011; 47(1):R1-10. DOI: 10.1530/JME-11-0022. View

Zhang S, Yan L, Cui C, Wang Z, Wu J, Zhao M . Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence. Oncol Rep. 2020; 44(2):565-576. PMC: 7336505. DOI: 10.3892/or.2020.7635. View

Denley A, Wallace J, Cosgrove L, Forbes B . The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res. 2004; 35(11-12):778-85. DOI: 10.1055/s-2004-814157. View

Mitani Y, Li J, Rao P, Zhao Y, Bell D, Lippman S . Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010; 16(19):4722-31. PMC: 5862426. DOI: 10.1158/1078-0432.CCR-10-0463. View

Cavalcante R, Nonaka C, de Pontes Santos H, Rabenhorst S, Pereira Pinto L, de Souza L . Assessment of CTNNB1 gene mutations and β-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas. Virchows Arch. 2018; 472(6):999-1005. DOI: 10.1007/s00428-018-2335-z. View

10.

Cantu G . Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from aetiopathogenesis to diagnosis. Acta Otorhinolaryngol Ital. 2021; 41(3):206-214. PMC: 8283400. DOI: 10.14639/0392-100X-N1379. View

11.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

12.

Thibodeau J, Bourgeois-Daigneault M, Lapointe R . Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology. 2012; 1(6):908-916. PMC: 3489746. DOI: 10.4161/onci.21205. View

13.

Nieman K, Romero I, Van Houten B, Lengyel E . Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013; 1831(10):1533-41. PMC: 3742583. DOI: 10.1016/j.bbalip.2013.02.010. View

14.

Lv S, Wang W, Wang H, Zhu Y, Lei C . PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019; 19(1):204. PMC: 6407222. DOI: 10.1186/s12885-019-5426-6. View

15.

Simpson A, Petnga W, Macaulay V, Weyer-Czernilofsky U, Bogenrieder T . Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol. 2017; 12(5):571-597. PMC: 5610669. DOI: 10.1007/s11523-017-0514-5. View

16.

Belfiore A, Genua M, Malaguarnera R . PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res. 2009; 2009:830501. PMC: 2709717. DOI: 10.1155/2009/830501. View

17.

Guo Y, Yu T, Yang J, Zhang T, Zhou Y, He F . Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis. Am J Cancer Res. 2016; 5(12):3600-11. PMC: 4731634. View

18.

Liu H, Huang G, Luo M . Transcriptome analyses identify hub genes and potential mechanisms in adenoid cystic carcinoma. Medicine (Baltimore). 2020; 99(2):e18676. PMC: 6959903. DOI: 10.1097/MD.0000000000018676. View

19.

Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H . Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007; 27(14):5105-19. PMC: 1951944. DOI: 10.1128/MCB.00162-07. View

20.

Tang Y, Liang X, Zheng M, Zhu Z, Zhu G, Yang J . Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. Oral Oncol. 2010; 46(4):311-6. DOI: 10.1016/j.oraloncology.2010.02.001. View